Advances in pharmaceutical treatment options for narcolepsy
Authors:
- 23 September 2018
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Orphan Drugs
- Vol. 6 (10) , 597-610
Abstract
Introduction: Narcolepsy is a syndrome characterized by excessive daytime sleepiness (EDS), cataplexy, and other abnormal manifestations of rapid eye movement sleep phenomena. Since hypocretin deficiency is presumed to be the main pathophysiology of narcoleptic symptoms, hypocretin replacement therapy would be promising; small molecule hypocretin receptor agonists and intranasal administration of hypocretin peptides are recognized as potential pharmaceutical treatments. Pitolisant, a histaminergic inverse agonist, recently became available in European countries for the treatment of EDS. Additionally, other emerging treatments such as immunotherapies, TRH analogs, and solriamfetol have been under investigation. Areas covered: The pathophysiology of narcolepsy is summarized, along with the current and emerging pharmaceutical treatments for narcolepsy. Expert opinion: Hypocretin replacement therapy might be the most straightforward and effective treatment to address both cataplexy and EDS. Although small molecule synthetic hypocretin receptor agonists and intranasal hypocretin administration have been developed, for hypocretin receptor agonists, only preliminary data are available, and the efficacy data for intranasal delivery in human subjects are also lacking. Recently, the U.S. FDA has accepted the New Drug Application of solriamfetol for excessive sleepiness. It is likely that other emerging treatments will also become available in the clinical setting in the future.Keywords
This publication has 123 references indexed in Scilit:
- Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexySleep Medicine, 2011
- Differential effects of acute and repeat dosing with the H3antagonist GSK189254 on the sleep–wake cycle and narcoleptic episodes in Ox−/− miceBritish Journal of Pharmacology, 2009
- Stimulation of orexin/hypocretin neurones by thyrotropin‐releasing hormoneThe Journal of Physiology, 2009
- Novel Vasoconstrictor Formulation to Enhance Intranasal Targeting of Neuropeptide Therapeutics to the Central Nervous SystemThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative diseaseBMC Neuroscience, 2008
- Manipulation of skin temperature improves nocturnal sleep in narcolepsyJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Trace amine-associated receptor 1—Family archetype or iconoclast?Pharmacology & Therapeutics, 2007
- Late-onset narcolepsy presenting as rapidly progressing muscle weakness: Response to plasmapheresisAnnals of Neurology, 2005
- The Effect of Hypocretin Replacement Therapy in a 3-Year-Old Weimaraner with NarcolepsyJournal of Veterinary Internal Medicine, 2004
- A Tale of Novel Intoxication: Seven Cases of γ-Hydroxybutyric Acid OverdoseAnnals of Emergency Medicine, 1998